News

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on his and colleagues’ study of single nucleotide polymorphisms in Huntington disease.

One of the first case-series studies that analyzed children with COVID-19 suggest that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.

The dual orexin receptor antagonist improved sleep maintenance and total sleep time without residual next-day effects.

New findings indicate that cognitive health in old age depends in part on cognitive development in early life.

Located in the “Stroke Belt” of the US, Virginia presents a unique perspective on the interplay of social, ethnic, and cultural implications on population health.

In part 1 of this interview, Daniel Ontaneda, MD, PhD, the co-principal of the CAVS-MS study, outlines the reasons for why the central vein sign can lower rates of misdiagnosing multiple sclerosis.

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Neurology News Network for the week ending July 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

An NIH-funded study provided supporting evidence of an association between high levels of gram-negative bacteria and a stroke-, seizure-, and headache-inducing vascular abnormality.

In the wake of the COVID-19 pandemic, health care providers and patients have had to quickly adapt to new formats of care models to promote safety while retaining care standards.

Fred Cohen, MD, offers insight on his study exploring the utility of combined Botox with anti-CGRP preventives for patients with chronic migraine.

Andrew Russman, DO, guest editor for NeurologyLive, provides insight on how stroke care has changed during the COVID-19 pandemic.

During DBS stimulation “on” periods, all patients experienced varying degrees of dysphagia, with significant improvements when stimulation was “off.”

Biohaven’s verdiperstat has entered a phase 3 trial for the treatment of multiple system atrophy, with a new drug application submission on the agenda for late 2021.

Kottil Rammohan, MD, director of the MS Division and Multiple Sclerosis Center of Excellence at the University of Miami, discussed the EMD Serono agent’s history and advantages for the patient community.

Notably, the cohort assessment did not identify a link between exposure to disease-modifying therapies and COVID-19 severity.

No differences were observed between the insulin and placebo groups on several clinical outcome measures as well as biomarker evaluations.

An in-depth look into the expanding landscape of multiple sclerosis treatments that target bruton tyrosine kinase.

People with Down syndrome may be a suitable population for clinical trials for Alzheimer disease as prevalence ranges from 90% to 100% by the seventh decade of life.